Kornimate/medical-research-clean huggingface dataset:
clinical evaluation of myday™ and 1-day acuvue® trueye®

Conditions: Refractive Error

Summary: the purpose of this study is to evaluate the functional vision of 2 daily disposable silicone hydrogel contact lenses using time controlled visual acuity (tcva) measurements at high luminance and high contrast after 10+/-3 days of wear post 3 hour exposure to a reduced humidity environment.

after randomization, participants attended a baseline visit to include a 3 hour exposure to reduced humidity environment. the participant's habitual lenses were worn for the baseline visit.

Eligibility criteria:
inclusion criteria: * must sign informed consent form. * adapted, current soft silicone hydrogel daily disposable contact lens wearer during the last 2 months. * willing to wear lenses every day or at least 5 days per week 6 hours per day. * willing to discontinue artificial tears and rewetting drops usage on the days of study visits. * other protocol-specified inclusion criteria may apply. exclusion criteria: * monocular (only 1 eye with functional vision) or fit with only 1 lens. * pregnant or lactating. * current myday™ or 1day acuvue® trueye® lens wearer. * any abnormal ocular condition as specified in the protocol. * other protocol-specified exclusion criteria may apply.

Keywords: contact lenses
effect of anti-epileptic drugs on etonogestrel-releasing implant pharmacokinetics in women with epilepsy

Conditions: Contraception; Drug Interactions

Summary: data on the interaction between the etonogestrel (eng) implant and antiepileptic drug (aed) regimen are scarce. we will evaluated the effect of 2 aed regimens (1 including carbamazepine and the other topiramate) on the pharmacokinetic (pk) parameters of an eng-releasing implant in women with epilepsy.


Eligibility criteria:
inclusion criteria: * women 18- 45 years old; * with regular menstrual cycles; * with bmi between 18 and 29.9 (kg/m2); * who has selected the eng implant as a contraceptive method; * using a stable antiepileptic drug regimen including carbamazepine or topiramate for ate least 3 months (only for women with epilepsy). exclusion criteria: * use of short-acting hormonal contraceptives in the month prior to enrollment; * use of depomedroxyprogesterone acetate in the 6 months prior to enrollment; * women with conditions classified as category 3 and/or 4 for etonogestrel implant use according to the world health organization medical eligibility criteria for contraceptive use; * drug or alcohol addiction; * use of other drugs metabolized by cyp3a4 30 days prior to enrollment; * non adherence to antiepileptic drug regimen (only for women with epilepsy); * illiteracy

Keywords: etonogestrel implant anti-epileptic drugs pharmacokinetics
labetalol infusion and dexmedetomidine infusion in hypotensive anesthesia

Conditions: Hypotensive Anesthesia; Ear, Nose and Throat Procedure

Summary: this study aims to compare between the role of labetalol infusion versus dexmedetomidine infusion in hypotensive anesthesia in ear, nose and throat surgeries.

hypotensive anaesthesia is the deliberate lowering of a patient's blood pressure during surgery. it is necessary during ear, nose and throat surgery for drying surgical field, ease in operation procedure and shortening of the duration of surgery. labetalol is a unique parenteral anti-hypertensive drug that has selective α1 and non- selective β adrenergic antagonist effects. in humans, the β to α blocking potency ratio is 7: 1 for iv labetalol. dexmedetomidine is highly selective alpha2 adrenergic agonist having several beneficial actions during the perioperative period. activation of alpha2 adrenergic receptors in the brain and spinal cord inhibits neuronal firing causing hypotension and bradycardia. this study was designed to compare between the role of labetalol infusion versus dexmedetomidine infusion in hypotensive anesthesia in ear, nose and throat surgeries.

Eligibility criteria:
inclusion criteria: * american society of anesthesiologists i, ii (asa i, ii) patients who were candidate for ear, nose and throat surgeries. * age: between 20 and 50 years exclusion criteria: * patients with uncontrolled hypertension, variable degrees of heart block, congestive cardiac failure, coagulopathy, cerebral insufficiency, hepatic or renal abnormality * patients on beta blocker or clonidine * pregnant or lactating females * patients who were allergic to any of the anesthetic or hypotensive drugs used in the study * patient refusal to be included in the trial

Keywords: hypotensive anesthesia labetalol dexmedetomidine
biomarkers in patients with stage iii or stage iv follicular lymphoma treated on clinical trial e-1496

Conditions: Lymphoma

Summary: rationale: studying samples of tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer. it may also help doctors predict how patients respond to treatment. purpose: this laboratory study is looking at biomarkers in patients with stage iii or stage iv follicular lymphoma treated on clinical trial e-1496.

objectives: * correlate gene expression profiles with progression-free survival (pfs) of patients with stage iii or iv follicular lymphoma treated with cyclophosphamide, vincristine, and prednisone with or without rituximab on clinical trial e-1496. * determine if immunoglobulin fc-gamma receptor polymorphisms are predictive of pfs in these patients. * assess the significance of the microenvironment by constructing tissue microarrays of follicular lymphoma and immunostaining with relevant biomarkers. * correlate relevant biomarkers with clinical features, response, and pfs. outline: this is a multicenter study. tissue samples are analyzed by gene expression profiling, microarrays to predict gene expression, immunohistochemistry, and immunoglobulin fc-gamma receptor polymorphism analysis for biological markers. projected accrual: a total of 175 samples will be accrued for this study.

Eligibility criteria:
disease characteristics: * diagnosis of follicular lymphoma * stage iii or iv disease * received cyclophosphamide, vincristine, and prednisone with or without rituximab on clinical trial e-1496 patient characteristics: * not specified prior concurrent therapy: * see disease characteristics

Keywords: stage iii grade 1 follicular lymphoma stage iii grade 2 follicular lymphoma stage iii grade 3 follicular lymphoma stage iv grade 1 follicular lymphoma stage iv grade 2 follicular lymphoma stage iv grade 3 follicular lymphoma
tele-rehabilitation in patients with temporomandibular dysfunction

Conditions: Temporomandibular Disorder; Temporomandibular Joint Disorders; Temporomandibular Joint Dysfunction Syndrome

Summary: temporomandibular disorder or tmd is characterized by a set of symptoms such as: pain, decreased range of motion and joint noise. it's origin is multifactorial, which may be related to biological aspects, environmental and psychosocial. the multimodal approach has been widely used in physiotherapy for the treatment of tmds. physiotherapy has been walking together with technology so that telerehabilitation can be a reality, contributing so that quality care reaches the patient, in the impossibility office-to-face service. the objective of this study is to verify the effect of telerehabilitation on pain outcomes, range of motion, functionality and biopsychosocial aspects in individuals with temporomandibular disorders. will be a randomized, controlled and blinded clinical trial was carried out. the study will be divided into two moments: evaluation and intervention. evaluations will be carried out using the diagnostic criteria for temporomandibular disorders: clinical protocol and assessment instruments (dc/tmd), the fonseca anamnesis index (iaf), the numerical pain scale (end) and the functional limitation questionnaire (mfiq). individuals will be randomized into 2 groups: group a (in person) group b (telerehabilitation). both groups will receive treatment physical therapy for 12 weeks. after collecting the data, they will be tabulated and analyzed using a 5% significance level.


Eligibility criteria:
1. age between 18 and 60 years; 2. presence of pain in the facial region in the last 6 months; 3. diagnosis of myalgia, arthralgia, headache attributed to temporomandibular disfunction and/or subluxation temporomandibular joint.

Keywords: temporomandibular joint disorders clinical protocols physiotherapy remote consultation telemedicine telehealth telerehabilitation teletherapy telepractice
effect of type 2 diabetes genetic risk information on health behaviors and outcomes

Conditions: Diabetes Mellitus, Type 2

Summary: the primary objective of the study is to assess the clinical utility of a genetic test for type 2 diabetes risk in combination with standardized risk assessment compared with standardized risk assessment alone, and to measure whether changes in perceived risk following genetic testing for type 2 diabetes risk are correlated with behavior change and increased concern about risk for type 2 diabetes.

one thousand outpatients will be enrolled over two years at two university-affiliated primary care clinics. patients will be assigned to one of three study arms: those who want genetic testing for diabetes risk will be randomly assigned to either receive the testing in addition to the sra (sra+g) or to receive the sra only (sra-only). those who do not wish to have genetic testing will receive the sra only. all patients will be surveyed at baseline, immediately after going through the sra (risk-counseling visit; 2-4 weeks after initial visit), at 3 months post risk counseling visit and at 12 months post risk counseling visit. bmi, waist circumference, fasting plasma glucose and insulin will be measured at baseline and 12 months. surveys will allow us to track patients' emotional responses to diabetes risk information and changing perceptions of personal risk for type 2 diabetes over time, and to see if these correlate with subsequent diet and exercise behaviors. we will use a linear model to assess the effects of genetic testing among the three study groups, using homeostasis model assessment of insulin resistance (homa-ir) and weight loss as the primary outcomes. we will use generalized linear ordinal regression models to fit the ordinal survey outcomes of risk perceptions to the continuous homa-ir and weight outcome variables.

Eligibility criteria:
inclusion criteria: * are male or female outpatients * no self-reported history of diabetes * no self-reported history of prior genetic testing for diabetes * not pregnant (self report) * are ≥18 and \<81 years of age * scheduled to receive serum glucose test in participating clinic * fasting at time of blood draw (no food or drink - except water - previous 8 hours: self report) * able and willing to give legally effective consent * able and willing to participate in patient questionnaires * ambulatory exclusion criteria: * previously or currently taking medications for lowering glucose (i.e., exenatide, pramlintide, metformin, rosiglitazone, pioglitazone, or future diabetes drugs) based on self-report and/or prescreening * self-report of current or prior diabetes diagnosis * self-reported prior history of genetic testing for diabetes * baseline serum glucose test result \>125

Keywords: predictive genomics personalized medicine personal genomics genetic knowledge genetic attitudes prevention health outcomes behavioral
medium-chain triglyceride oil massage on growth in preterm

Conditions: Preterm Infants; MCT Oil Massage; Growth

Summary: aim: to explore the effect of medium-chain triglyceride (mct) oil massage on growth in preterm infants. methods: this randomized controlled trial was conducted in the newborn center of a regional hospital in taiwan. preterm infants weighing between 1500 and 2000 g were recruited and randomly assigned to three groups: the mct oil massage, massage alone and no massage groups. the massages were given three times per day for 7 consecutive days. weight, length and head circumference were measured in the three groups at birth and on study days 1 to 7.


Eligibility criteria:
inclusion criteria: 1. gestational age between 28 and 37 weeks; 2. weight between 1500 and 2000 g after enrollment; 3. medically stable condition; 4. ≥120 cc per day feeding. exclusion criteria: 1. congenital anomalies; 2. skin disease; 3. requirement for mechanical ventilation; 4. requirement for o2 therapy; 5. presence of fracture.
remote exercise and nutritional prehabilitation for pancreatic cancer

Conditions: Pancreatic Cancer

Summary: the purpose of the study is to examine the feasibility and acceptability of an exercise and nutrition "prehabilitation" program for patients preparing for pancreatic cancer resection (removal).


Eligibility criteria:
inclusion criteria: * age 18 years or older * biopsy-proven pancreatic ductal adenocarcinoma (pdac), borderline resectable at diagnosis * eastern cooperative oncology group (ecog) performance status 0-2 * undergoing neoadjuvant chemotherapy with treatment plan including chemoradiation therapy and surgical resection * ability to read and speak english exclusion criteria: * regular engagement in rt (2x/week targeting all major muscle groups) * screen failure for exercise safety based on par-q * underlying unstable cardiac or pulmonary disease or symptomatic cardiac disease * recent fracture or acute musculoskeletal injury that precludes ability to participate in rt * numeric pain rating scale greater than or equal to a 7 out of 10 * myopathic or rheumatologic disease that impacts physical function
transfusion surveillance in anaesthesia

Conditions: Transfusion Reaction; Transfusion Related Complication; Anesthesia; Anesthesia; Shock; Side Effect; Fresh Blood Stool; Blood Coagulation Disorder; Blood Loss

Summary: the aim of this register is to collect exhaustively the different data available surrounding a transfusion act in the context of an active haemorrhage. the aim is to allow different modelling and analysis related to emergency transfusion.

the aim of this register is to collect exhaustively the different data available surrounding a transfusion act in the context of an active haemorrhage. the aim is to allow different modelling and analysis related to emergency transfusion. patients will be informed at the time of the anaesthesia consultation about the inclusion in the registry. the data will be collected from the patients' files by the investigators of the centre without modifying their management. the data collection period will not exceed the period of acute management.

Eligibility criteria:
inclusion criteria: * all patients who have received an hemostasis product exclusion criteria: * patient who refused to consent to data analysis and study participation

Keywords: transfusion monitoring emergency situation shock fresh frozen plasma
primary aldosteronism lc-ms/ms-specific cutoffs

Conditions: Primary Aldosteronism

Summary: aims to evaluation the lc-ms/ms-specific cutoffs of pa screening and cct test.

plasma aldosterone concentration and plasma renin activity / concentration measurement are important for early screening and diagnosis of primary aldosteronism (pa), most measurement methods are currently based on chemiluminescence, which may be cross-reactivity with other compounds and metabolites, leading to misdiagnosis or missed diagnosis of pa patients. liquid chromatography tandem mass spectrometry (lc-ms/ms) has been introduced into the clinical routine analysis of steroid hormones due to its higher specificity and is increasingly used for the diagnosis of adrenal diseases. however, it is unknown for the cut-offs of pa screening and cct test based on this technology in china. therefore, the purpose of this study is to establish the screening and cct cut-off point for primary aldosteronism based on lc-ms/ms technique at multicenter in china.

Eligibility criteria:
inclusion criteria: 1. age is between 18-75 years old. 2. hypertension patients with high risk factors for pa (meeting one of the following criteria): a.persistent hypertension (\> 150 / 100mmhg); b. refractory hypertension (combined with 3 antihypertensive drugs and one used as a diuretic,blood pressure is still greater than 140 / 90 mmhg or four antihypertensive drugs are needed to control blood pressure of less than 140 / 90 mmhg); c.hypertension with adrenal accidental tumor; d.hypertension is associated with hypokalaemia; 3. recent and stable use of antihypertensive drugs for more than 2 weeks, the drug types may include: β receptor blockers, ccb(calcium channel blockers), angiotension converting enzyme inhibitors(acei), angiotensin receptor blocker(arb), mineralocorticoid receptor antagonists(mra), and other diuretics. exclusion criteria: 1. patients who are unwilling to participate and complete the study or refuse to sign a written informed consent for the study; 2. patients diagnosed with other secondary hypertension (such as renal hypertension, renal artery stenosis, pheochromocytoma, cushing's syndrome, etc.); 3. combined with severe renal insufficiency egfr \<30 ml/min / 1.73 m2, or patients with liver insufficiency or liver failure (alanine aminotransferase and / or aspartate aminotransferase increased 2.5 times above the upper limit of normal); 4. clinical assessment of a dressing change risk, including: heart failure (nyha stage grade ii or above), any one or more of the stroke, myocardial infarction, and unstable angina pectoris diagnosed within three months; 5. patients who are pregnant or who are currently being treated with sex hormones and glucocorticoids; 6. incurable malignancy; 7. other reasons make it difficult to change or stop the drug to complete the diagnosis.

Keywords: diagnostic multicenter study
covid imaging with positron emission tomography

Conditions: Coronavirus Infection

Summary: we aim to study if metabolic intensity and extent according to pathologic pulmonary 18f-2-fluoro-2-deoxy-d-glucose (fdg)-uptake may correlate with the course of covid-19 pneumonia and potentially yield prognostic value. moreover, we aim to assess permanent changes after severe acute respiratory syndrome coronavirus 2 (sars-cov-2) infection, such as pulmonary fibrosis and neuropsychiatric symptoms (anosmia, depression, fatigue) where evaluation with fdg-positron emission tomography (pet/ct) might have an impact on further patient care.

several case studies confirmed increased fdg-uptake on pet scans corresponding to typical pulmonary lesions on chest ct scans in patients with covid-19 pneumonia. furthermore, increased fdg-uptake most likely caused by inflammatory changes in sars-cov-2 infection were described in other organs, such as mediastinal lymph nodes, bone marrow, and the spleen. as covid-19 frequently presents with anosmia and on rare occasions, symptoms of encephalitis, metabolic changes in the central nervous system (cns) were also investigated by fdg-pet/ct, showing hypometabolism in the olfactory gyrus and the limbic system, while hypermetabolism was observed in the basal ganglia and the cerebellar vermis. late changes in pulmonary ct-morphology, most commonly interstitial thickening and crazy paving are observed, suggesting permanent lung damage after sars-cov-2 infection in certain cases. evaluation of metabolic activity of acute and late inflammatory changes could potentially provide clinical benefit as dedicated medication could be started to prevent further organ damage due to prolonged inflammation. we aim to evaluate metabolic alterations in the lung parenchyma and potential extrapulmonary locations related to to covid-19 with fdg-pet/ct.

Eligibility criteria:
inclusion criteria: * inpatients with rt-pcr proven sars-cov-2 infection of the department of pulmonology of semmelweis university exclusion criteria: * age\<40 years for men and \<45 years for women * pregnancy * clinically unstable patients * patients in need of mechanical ventilation support * patients with known malignant disease

Keywords: covid19 pet-ct brain lung
mentors in motion: a physical activity intervention for obese adolescents

Conditions: Obesity

Summary: assesing the impact of mentoring on the lifestyle choices of adolescents who are overweight

randomized controlled trial of the impact of weekly contacts with mentors to improve physical activity pattern, self esteem, and weight loss in obese teenagers over a 6 month period.

Eligibility criteria:
inclusion criteria: * 13-17 yo able to participate in physical activity exclusion criteria: * on medications that could affect weight

Keywords: obesity mentoring fitness self-esteem
serum uromodulin and dn systematic review and meta analysis

Conditions: Diabetic Nephropathies

Summary: several studies have investigated the association between the changes of serum uromodulin and diabetic nephropathy (dn). however, the results are still controversial. hence, this meta-analysis aimed to evaluate the association of uromodulin with dn.


Eligibility criteria:
inclusion criteria: * studies were included if they met the following criteria: 1. serum level of uromodulin was determined; 2. the samples were enrolled from diabetic patients; 3. mean ± sd was reported for uromodulin between patients with and without dn; 4. the level of albumin to creatinine ratio (acr), glomerular filtration rate (gfr), or albumin excretion rate (aer) in patients with dn was determined exclusion criteria: * studies were excluded according to the following criteria: 1. duplicate studies; 2. review articles; 3. non original research articles; 4. studies with insufficient data to extract; 5. non-human research; 6. studies that determined urine level of uromodulin.

Keywords: dkd, urimodulin
a study to assess the rate of hospitalization in participants with schizophrenia treated with antipsychotics

Conditions: Schizophrenia

Summary: the primary purpose of the study is to compare the rate of hospitalization associated with psychotic relapse in participants with schizophrenia treated one year before with oral antipsychotics and one year after with long acting injectable atypical antipsychotics.

this is a retrospective (take a look back at events that already have taken place), observational, multicenter (when more than one hospital or medical school team work on a medical research study) study to review medical records of adults with a diagnosis of schizophrenia during the time period from 01 january 2009 through 31-december-2013 (only for mexican population). data will be collected from clinical practice. the medical records of participants will be screened and eligible participants data will be collected. the period of observation will span from 12 months before initial long acting injectable (lai) use and in 12 months after the initial lais use. the rate of hospitalization will be primarily evaluated.

Eligibility criteria:
inclusion criteria: * out-patients with the main diagnosis of schizophrenia with diagnostic and statistical manual of mental disorders (dsm-4 criteria) * only clinical records with complete information during the 2 years period selected for data analysis will be included * participants treated with oral antipsychotics then switched to long acting injectable (lai) due to poor adherence, lack of efficacy (no significant symptom reduction, judged by physician, at maximum recommended dose of an antipsychotic for 6 weeks), or participants choice, (excluding for the brazil population, when the switch has not been clearly justified or the switch has not been done during hospitalization) * being regularly treated with lai atypical antipsychotics for at least 1 year after the initial use of lai atypical antipsychotics exclusion criteria: * participants with refractory schizophrenia (rs) * participants that started lai treatment as in-patients and patients that switched to lai during hospitalization (only for mexican population).

Keywords: schizophrenia oral antipsychotics long acting injectable antipsychotics